Evidence map›Paper›PMID 25728608›Full record

ArticleThe Prostate2015

SLUG is a direct transcriptional repressor of PTEN tumor suppressor.

Berna Uygur, Katrina Abramo, Evgenia Leikina, Calvin Vary, Lucy Liaw, Wen-Shu Wu

Abstract read
In one paragraph

Article in The Prostate, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 42 citations in OpenAlex.

  1. COPS5 inhibition synergizes with the antitumor effect of trastuzumab by PTEN upregulation in HER2-amplified gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Berna UygurCenter for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine; Program in Biochemistry and Molecular Biology, University of Maine, Orono, Maine; Section on Membrane Biology, Program of Physical Biology, Eunice Kennedy Shriver National, Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
Katrina Abramo
Evgenia Leikina
Calvin Vary
Lucy Liaw
Wen-Shu Wu
Maine Medical Center Research Institute · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USIllinois College · USNational Institutes of Health · US

Funding

Protein-mediated membrane remodelingZIAHD001501 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI CHERNOMORDIK, LEONID V. · 2009 to 2025
$30.7M
Role of slug in hematopoietic stem cell regenerationR01DK090478 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI WU, WEN-SHU · 2011 to 2015
$1.7M
Regulatory Role of Transcription Factor Slug in AgingR01AG040182 · NIA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI WU, WEN-SHU · 2011 to 2015
$1.6M
Intramural NIH HHSNIA NIH HHS R01 AG040182NIA NIH HHS R01AG040182NIDDK NIH HHS R01 DK090478NIDDK NIH HHS R01DK090478PHS HHS 2008610038
6 · The paper itself

Abstract

backgroundPTEN/AKT signaling plays a key role in prostate cancer development and maintenance of prostate cancer stem cells. How other oncogenes or tumor suppressors interact with this pathway remain to be elucidated. SLUG is an zinc finger transcription factor of the Snail superfamily, and it promotes cancer metastasis and determines the mammary stem cell state.

methodsSLUG was overexpressed in cells by retroviral vector and knockdown of SLUG and PTEN was mediated by shRNAs-expressing lentiviruses. Expression level of SLUG and PTEN was examined by Western blot, RT-PCR, and qPCR analyses. PTEN promoter activity was measured by luciferase reporter assay. ChIP assay was used to measure the binding between SLUG and the PTEN promoter in vivo.

resultWe showed that overexpression of SLUG decreased expression of PTEN tumor repressor in prostate cancer cell lines 22RV1 and DU145; conversely, knockdown of SLUG expression elevated PTEN expresson at both protein and RNA level in these cells. We demonstrated that SLUG overexpression inhibits PTEN promoter activity through the proximal promoter region in prostate cancer cells. By ChIP assay, we confirmed that SLUG directly binds to the PTEN promoter region covering the E-box sites. We also showed that Slug deficiency leads to an increased expression of PTEN in mouse embryo fibroblasts and prostate tissues. Importantly, we found that overexpression of SLUG increases drug resistance of DU145 prostate cancer cell line and knockdown of SLUG by shRNA sensitizes DU145 cell line to chemotherapeutic drugs. We further demonstrated that PTEN knockdown converts drug sensitivity of DU145 cells expressing SLUG shRNA to anticancer drugs.

conclusionWe provide compelling evidence showing that PTEN is a direct functional target of SLUG. Our findings offer new insight in the regulation of the PTEN/AKT pathway and provide a molecular basis for potential targeted therapies of prostate cancer Prostate 75:907-916, 2015. © 2015 Wiley Periodicals, Inc.

Indexed as

AnimalsBlotting, WesternCell Line, TumorGene Expression Regulation, NeoplasticGene Knockdown TechniquesHEK293 CellsHumansImmunohistochemistryMaleMiceMice, KnockoutMice, TransgenicPromoter Regions, GeneticProstatic NeoplasmsPTEN PhosphohydrolaseReverse Transcriptase Polymerase Chain ReactionPTEN PhosphohydrolasePTEN protein, humanRNA, NeoplasmRNA, Small InterferingSNAI1 protein, humanSnai2 protein, mouseSnail Family Transcription FactorsTranscription Factorscell growthprostate cancerPTENslugtumor suppressor

Identifiers

PMID25728608
PMCPMC4654464
OpenAlexW2142781168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.